Zcash (ZEC) has expanded its presence in the U.S. market through multiple channels: Cypherpunk Technologies holds nearly 1.92% of ZEC supply in its corporate treasury, valued at $129 million as of June 30, with significant unrealized gains. Grayscale launched a Zcash ETF (ZCSH) on NYSE Arca, providing regulated investment access with Coinbase as custodian. Additionally, Robinhood lists ZEC for trading, and Gemini supports Zcash credit card rewards and wallet features. These diverse exposures enhance Zcash's accessibility and investment appeal in the U.S., though ETF and brokerage holdings differ from direct use of Zcash’s privacy features.
Zcash's market presence is highlighted by Cypherpunk Technologies holding nearly 1.92% of its supply valued at $129 million as of June 30. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Sep 23, 2026 20:03 WIB: out of 50 major cryptocurrencies, 29 rose and 20 fell. Notable movers include Bitcoin Cash (BCH) with a 16.21% increase to Rp6.366.202, The Graph (GRT) up 13.49% at Rp482, and Harmony (ONE) down 17.20% at Rp55, with typical hold times ranging from 68 to 152 days and varied buy/sell order activity.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
